Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity
摘要:
Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy. Herein, we describe our efforts toward the discovery of a series of 5-chloro-N-4-phenyl-N-2(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as dual CDK6 and 9 inhibitors. Intensive structural modifications lead to the identification of compound 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2. Further biological studies revealed that compound 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis. More importantly, compound 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment. Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.
组织蛋白酶 C (Cat C) 通过影响中性粒细胞丝氨酸蛋白酶 (NSP) 的激活参与炎症和免疫调节。因此,组织蛋白酶 C 是治疗 NSP 相关炎症性疾病的一个有吸引力的靶点。在此,从命中发现、结构优化和先导化合物发现三个方面描述了第一个强效“非肽基非共价组织蛋白酶C抑制剂”的完整发现过程。从hit 14开始,全面开展了基于结构的优化和构效关系研究,发现先导化合物54在体内和体外均是一种有效的类药组织蛋白酶C抑制剂。此外,化合物54 (与组织蛋白酶 C Enz IC 50 = 57.4 nM)在慢性阻塞性肺病动物模型中表现出有效的抗炎活性。这些结果证实了非肽基和非共价衍生物可以用作有效的组织蛋白酶C抑制剂,并鼓励我们在此发现的基础上继续进一步的药物发现。
Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophene-substituted pyridine: Design, structure-activity relationship and anti-inflammatory activity in vivo
作者:Xing Chen、Yaoyao Yan、Juncheng Du、Xiaobao Shen、Chuanbiao He、Haitao Pan、Jun Zhu、Xinhua Liu